Protozoan encounters with Toll-like receptor signalling pathways: Implications for host parasitism

Nature Reviews Immunology

Volumn 6, Issue 12, 2006, Pages 895-906

  Gazzinelli, Ricardo T ^a,b,c   Denkers, Eric Y ^d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; FLAGELLIN; IMIQUIMOD; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; LIGAND; LIPID A; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; VACCINE;

HUMAN; NONHUMAN; PARASITE SURVIVAL; PARASITISM; PARASITOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTOZOON; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HOST-PARASITE RELATIONS; MICE; PROTOZOA; PROTOZOAN INFECTIONS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 33845204804     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1978     Document Type: Review

References (121)

1. Janeway, C. A. Jr. & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
2. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
3. Dobrovolskaia, M. A. & Vogel, S. N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4, 903-914 (2002).
4. Lien, E. & Ingalls, R. R. Toll-like receptors. Crit. Care Med. 30, S1-S11 (2002).
5. Janeway, C. A. Jr. How the immune system works to protect the host from infection: a personal view. Proc. Natl Acad. Sci. USA 98, 7461-7468 (2001).
6. Gazzinelli, R. T., Ropert, C. & Campos, M. A. Role of the Toll/interleukin-1 receptor signaling pathway in host resistance and pathogenesis during infection with protozoan parasites. Immunol. Rev. 201, 9-25 (2004).
7. Camargo, M. M. et al. Glycosylphosphatidylinositol-anchored mucin-like glycoproteins isolated from Trypanosoma cruzi trypomastigotes initiate the synthesis of proinflammatory cytokines by macrophages. J. Immunol. 158, 5890-5901 (1997).
8. de Veer, M. J. et al. MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur. J. Immunol. 33, 2822-2831 (2003).
9. Debierre-Grockiego, F. et al. Roles of glycosylphosphatidylinositols of Toxoplasma gondii. Induction of tumor necrosis factor-α production in macrophages. J. Biol. Chem. 278, 32987-32993 (2003). An important study revealing that T. gondii GPI anchors also have pro-inflammatory properties. The study uses synthetic GPI anchors and lends support to the idea that protozoan GPI anchors are a major class of PAMPs.
10. Magez, S. et al. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J. Immunol. 160, 1949-1956 (1998).
11. Schofield, L. & Hackett, F. Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J. Exp. Med. 177, 145-153 (1993).
12. Camargo, M. M., Andrade, A. C., Almeida, I. C., Travassos, L. R. & Gazzinelli, R. T. Glycoconjugates isolated from Trypanosoma cruzi but not from Leishmania species membranes trigger nitric oxide synthesis as well as microbicidal activity in IFN-γ-primed macrophages. J. Immunol. 159, 6131-6139 (1997).
13. Talvani, A. et al. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-γ as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect. 2, 851-866 (2000).
14. Ferguson, M. A. J. The structure, biosynthesis and functions of glycosylphosphatidylinositol anchor, and the contributions of trypanosome research. J. Cell Sci. 112, 2799 (1999).
15. Almeida, I. C. & Gazzinelli, R. T. Proinflammatory activity of glycosylphosphatidylinositol anchors derived from Trypanosoma cruzi: structural and functional analyses. J. Leukoc. Biol. 70, 467-477 (2001).
16. Campos, M. A. S. et al. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J. Immunol. 167, 416-423 (2001). Establishes that the pro-inflammatory activity of T. cruzi-derived GPI anchors is mediated by TLR2.
17. Petersen, C. A., Krumholz, K. A. & Burleigh, B. A. Toll-like receptor 2 regulates interleukin-1β-dependent cardiomyocyte hypertrophy triggered by Trypanosoma cruzi. Infect. Immun. 73, 6974-6980 (2005).
18. Ropert, C. & Gazzinelli, R. T. Regulatory role of Toll-like receptor 2 during infection with Trypanosoma cruzi. J. Endotoxin Res. 10, 425-430 (2004).
19. Oliveira, A. C. et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J. Immunol. 173, 5688-5696 (2004).
20. McConville, M. J., Schnur, L. F., Jaffe, C. & Schneider, P. Structure of Leishmania lipophosphoglycan: inter- and intra-specific polymorphism in Old World species. Biochem. J. 310, 807-818 (1995).
21. Becker, I. et al. Leishmania lipophosphoglycan (LPG) activates NK cells through Toll-like receptor-2. Mol. Biochem. Parasitol. 130, 65-74 (2003).
22. Flandin, J. F., Chano, F. & Descoteaux, A. RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-γ-primed macrophages. Eur. J. Immunol. 36, 411-420 (2006).
23. Krishnegowda, G. et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatid ylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem. 280, 8606-8616 (2005).
24. Naik, R. S. et al. Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J. Exp. Med. 192, 1563-1576 (2000).
25. Ouaissi, A. et al. The Trypanosoma cruzi Tc52-released protein induces human dendritic cell maturation, signals via Toll-like receptor 2, and confers protection against lethal infection. J. Immunol. 168, 6366-6374 (2002).
26. Harris, T. H., Cooney, N. M., Mansfield, J. M. & Paulnock, D. M. Signal transduction, gene transcription, and cytokine production triggered in macrophages by exposure to trypanosome DNA. Infect. Immun. 74, 4530-4537 (2006).
27. Shoda, L. K. et al. DNA from protozoan parasites Babesia bovis, Trypanosoma cruzi, and T. brucei is mitogenic for B lymphocytes and stimulates macrophage expression of interleukin-12, tumor necrosis factor α, and nitric oxide. Infect. Immun. 69, 2162-2171 (2001).
28. Brown, W. C. & Corral, R. S. Stimulation of B lymphocytes, macrophages, and dendritic cells by protozoan DNA. Microbes Infect. 4, 969-974 (2002).
29. H1-cell responses and optimal protection against T. cruzi involve the coordinated activity of multiple TLRs, including TLR9 and TLR2.
30. Drennan, M. B. et al. The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent. J. Immunol. 175, 2501-2509 (2005).
31. Gardner, M. J. et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-511 (2002).
32. Jaramillo, M., Gowda, D. C., Radzioch, D. & Olivier, M. Hemozoin increases IFN-γ-inducible macrophage nitric oxide generation through extracellular signal-regulated kinase- and NF-κB-dependent pathways. J. Immunol. 171, 4243-4253 (2003).
33. Jaramillo, M. et al. Hemozoin-inducible proinflammatory events in vivo: potential role in malaria infection. J. Immunol. 172, 3101-3110 (2004).
34. Pichyangkul, S., Saengkrai, P. & Webster, H. K. Plasmodium falciparum pigment induces monocytes to release high levels of tumor necrosis factor-α and interleukin-1β. Am. J. Trop. Med. Hyg. 51, 430-435 (1994).
35. Coban, C. et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. 201, 19-25 (2005). Reports the surprising finding that haemozoin is recognized by TLR9, which is more commonly known as a detector of hypomethylated bacterial DNA containing CpG motifs.
36. Yarovinsky, F. et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 308, 1626-1629 (2005). Identifies the first chemical ligand of TLR11, a T. gondii profilin-like protein. Importantly, Tlr11 knockout increases susceptibility to this parasite, although not as dramatically as Myd88 knockout.
37. Aosai, F. et al. Toxoplasma gondii-derived heat shock protein HSP70 functions as a B cell mitogen. Cell Stress Chaperones 7, 357-364 (2002).
38. Del Rio, L. et al. Toxoplasma gondii triggers myeloid differentiation factor 88-dependent IL-12 and chemokine ligand 2 (monocyte chemoattractant protein 1) responses using distinct parasite molecules and host receptors. J. Immunol. 172, 6954-6960 (2004).
39. O'Neill, L. A., Fitzgerald, K. A. & Bowie, A. G. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 24, 286-290 (2003).
40. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143-150 (1998).
41. Takeuchi, O. & Akira, S. MyD88 as a bottle neck in Toll/IL-1 signaling. Curr. Top. Microbiol. Immunol. 270, 155-167 (2002).
42. Fitzgerald, K. A. et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413, 78-83 (2001).
43. Fitzgerald, K. A. et al. LPS/TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198, 1043-1055 (2003).
44. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301, 640-643 (2003).
45. Horng, T., Barton, G. M., Flavell, R. A. & Medzhitov, R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature 420, 329-333 (2002).
46. Yamamoto, M. et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 420, 324-329 (2002).
47. Campos, M. A. et al. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J. Immunol. 172, 1711-1718 (2004). Shows the involvement of MyD88-dependent and MyD88-independent pathways in the induction of IL-12, IFNγ and host resistance to the protozoan parasite T. cruzi.
48. H2 response. J. Immunol. 170, 4237-4241 (2003).
49. Scanga, C. A. et al. MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J. Immunol. 168, 5997-6001 (2002). The first evidence that Myd88 knockout dramatically increases susceptibility to T. gondii. The study directly implicates TLRs in resistance to protozoan infection.
50. Stevenson, M. M. & Riley, E. M. Innate immunity to malaria. Nature Rev. Immunol. 4, 169-180 (2004).
51. Adachi, K. et al. Plasmodium berghei infection in mice induces liver injury by an IL-12- and Toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J. Immunol. 167, 5928-5934 (2001). Shows the important principle that signalling through MyD88 can have negative consequences for the host during protozoan infection. This is a significant caveat when considering TLR ligands as immunotherapeutic tools.
52. Chen, M. et al. Involvement of MyD88 in host defense and the down-regulation of anti-heat shock protein 70 autoantibody formation by MyD88 in Toxoplasma gondii-infected mice. J. Parasitol. 88, 1017-1019 (2002).
53. Kropf, P. et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 72, 1920-1928 (2004).
54. Mun, H. S. et al. TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection. Int. Immunol. 15, 1081-1087 (2003).
55. Monteiro, A. C. et al. Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type-1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi. J. Immunol. 177, 6325-6335 (2006).
56. Petska, S. et al. Interleukin-10 and related cytokines and receptors. Annu. Rev. Immunol. 22, 929-979 (2004).
57. + T cells and accompanied by overproduction of IL-12, IFN-γ, and TNF-α. J. Immunol. 157, 798-805 (1996).
58. Suzuki, Y. et al. IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J. Immunol. 164, 5375-5382 (2000).
59. Hunter, C. A. et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J. Immunol. 158, 3311-3316 (1997).
60. Kossodo, S. et al. Interleukin-10 modulates susceptibility in experimental cerebral malaria. Immunology 91, 536-540 (1997).
61. Kurtzhals, J. A. et al. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. Lancet 351, 1768-1772 (1998).
62. Sanni, L. A., Jarra, W., Li, C. & Langhorne, J. Cerebral edema and cerebral hemorrhages in interleukin-10-deficient mice infected with Plasmodium chabaudi. Infect. Immun. 72, 3054-3058 (2004).
63. Belkaid, Y. et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194, 1497-1506 (2001).
64. Buzoni-Gatel, D. et al. Murine ileitis after intracellular parasite infection is controlled by TGF-β-producing intraepithelial lymphocytes. Gastroenterology 120, 914-924 (2001).
65. Gantt, K. R. et al. Activation of TGF-β by Leishmania chagasi: importance for parasite survival in macrophages. J. Immunol. 170, 2613-2620 (2003).
66. Gazzinelli, R. T., Oswald, I. P., James, S. & Sher, A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-γ activated macrophages. J. Immunol. 148, 1792-1796 (1992).
67. Li, C., Sanni, L. A., Omer, F., Riley, E. & Langhorne, J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10- deficient mice are ameliorated by anti-tumor necrosis factor α and exacerbated by anti-transforming growth factor β antibodies. Infect. Immun. 71, 4850-4856 (2003).
68. Silva, J. S. et al. Interleukin-10 and interferon-γ regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 175, 539-545 (1992).
69. Scharton-Kersten, T., Afonso, L. C., Wysocka, M., Trinchieri, G. & Scott, P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J. Immunol. 154, 320-330 (1995).
70. Gazzinelli, R. T., Oswald, I. P., Hieny, S., James, S. & Sher, A. The microbicidal activity of interferon-γ-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β. Eur. J. Immunol. 22, 2501-2506 (1992).
71. Silva, S. J., Twardzik, D. R. & Reed, S. G. Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor-β (TGF-β). J. Exp. Med. 174, 539-545 (1991).
72. 4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J. Exp. Med. 196, 1253-1262 (2002).
73. Bannenberg, G. L., Aliberti, J., Hong, S., Sher, A. & Serhan, C. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J. Exp. Med. 199, 515-523 (2004).
74. Butcher, B. A. & Denkers, E. Y. Mechanism of entry determines ability of Toxoplasma gondii to inhibit macrophage proinflammatory cytokine production. Infect. Immun. 70, 5216-5224 (2002).
75. Denkers, E. Y., Kim, L. & Butcher, B. A. In the belly of the beast: subversion of macrophage proinflammatory signaling cascades during Toxoplasma gondii infection. Cell. Micro. 5, 75-83 (2003).
76. McKee, A. S., Dzierszinski, F., Boes, M., Roos, D. S. & Pearce, E. J. Functional inactivation of immature dendritic cells by the intracellular parasite Toxoplasma gondii. J. Immunol. 173, 2632-2640 (2004).
77. Bennouna, S., Sukhumavasi, W. & Denkers, E. Y. Toxoplasma gondii inhibits Toll-like receptor (TLR)4 ligand-induced mobilization of pre-formed TNF-α in mouse peritoneal neutrophils. Infect. Immun. 74, 4274-4281 (2006).
78. Williams, L., Bradley, L., Smith, A. & Foxwell, B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172, 567-576 (2004).
79. Butcher, B. A. et al. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-α in host macrophages. J. Immunol. 174, 3148-3152 (2005). Shows that T. gondii directly triggers STAT3 activation during infection, resulting in downregulation of pro-inflammatory cytokines and highlights a novel mechanism of interference with TLR signalling.
80. Kim, L., Butcher, B. A. & Denkers, E. Y. Toxoplasma gondii interferes with lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms distinct from endotoxin tolerance. J. Immunol. 172, 3003-3010 (2004).
81. Dobrovolskaia, M. A. et al. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR 'homotolerance' versus 'heterotolerance' on NF-κB signaling pathway components. J. Immunol. 170, 508-519 (2003).
82. Sato, S. et al. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and independent pathways. Int. Immunol. 14, 783-791 (2002).
83. Butcher, B. A., Kim, L., Johnson, P. F. & Denkers, E. Y. Toxoplasma gondii tachyzoites inhibit proinflammatory cytokine induction in infected macrophages by preventing nuclear translocation of the transcription factor NFκB. J. Immunol. 167, 2193-2201 (2001). One of the first studies to show that intracellular T. gondii infection renders macrophages nonresponsive to LPS. Simultaneously, the cells have impaired NF-κB nuclear translocation.
84. Shapira, S. S., Speirs, K., Gerstein, A., Caamano, J. & Hunter, C. A. Suppression of NF-κB activation by infection with Toxoplasma gondii. J. Infect. Dis. 185, S66-S72 (2002).
85. Shapira, S. et al. Initiation and termination of NFκB signaling by the intracellular protozoan parasite Toxoplasma gondii. J. Cell Sci. 118, 3501-3508 (2005).
86. Robben, P. M. et al. Production of IL-12 by macrophages infected with Toxoplasma gondii depends on the parasite genotype. J. Immunol. 172, 3686-3694 (2004).
87. Weinheber, N., Wolfram, M., Harbecke, D. & Aebischer, T. Phagocytosis of Leishmania mexicana amastigotes by macrophages leads to a sustained suppression of IL-12 production. Eur. J. Immunol. 28, 2467-2477 (1998).
88. Cameron, P. et al. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cyteine proteases and the NFκB signaling pathway. J. Immunol. 173, 3297-3304 (2004).
89. Feng, G.-J. et al. Extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases differentially regulate the lipopolysaccharide-mediated induction of inducible nitric oxide synthase and IL-12 in macrophages: Leishmania phosphoglycans subvert macrophage IL-12 production by targeting ERK MAP kinase. J. Immunol. 163, 6403-6412 (1999).
90. H responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171, 4984-4989 (2003).
91. Ropert, C. et al. Requirement of mitogen-activated protein kinases and IκB phosphorylation for induction of proinflammatory cytokines synthesis by macrophages indicates functional similarity of receptors triggered by glycosylphosphatidylinositol anchors from parasitic protozoa and bacterial lipopolysaccharide. J. Immunol. 166, 3423-3431 (2001).
92. Ropert, C., Closel, M., Chaves, A. C. & Gazzinelli, R. T. Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associate kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages. J. Immunol. 171, 1456-1465 (2003).
93. Marth, T. & Kelsall, B. L. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 185, 1987-1995 (1997).
94. Blanchette, J., Racette, N., Faure, R., Siminovitch, K. A. & Olivier, M. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-γ-triggered JAK2 activation. Eur. J. Immunol. 29, 3737-3744 (1999).
95. Forget, G. et al. Role of host phosphotyrosine phosphatase SHP-1 in the development of murine leishmaniasis. Eur. J. Immunol. 31, 3185-3196 (2001).
96. Grazia Cappiello, M., Sutterwala, F. S., Trinchieri, G., Mosser, D. M. & Ma, X. Suppression of Il-12 transcription in macrophages following Fcγ receptor ligation. J. Immunol. 166, 4498-4506 (2001).
97. Kane, M. M. & Mosser, D. M. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166, 1141-1147 (2001).
98. Ocana-Morgner, C., Mota, M. M. & Rodriguez, A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J. Exp. Med. 197, 143-151 (2003).
99. Perry, J. A., Olver, C. S., Burnett, R. C. & Avery, A. C. The acquisition of TLR tolerance during malaria infection impacts T cell activation. J. Immunol. 174, 5921-5925 (2005).
100. Urban, B. C. et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400, 73-77 (1999). Shows that erythrocytes infected with Plasmodium spp. block LPS-induced DC maturation through adhesive interactions with CD36. Such parasite-induced suppression might help to explain the lack of protective immunity in populations that are continually exposed to the malaria parasite.
101. Urban, B. C., Willcox, N. & Roberts, D. J. A role for CD36 in the regulation of dendritic cell function. Proc. Natl Acad. Sci. USA 98, 8750-8755 (2001).
102. Millington, O. R., Di Lorenzo, C., Phillips, R. S., Garside, P. & Brewer, J. M. Suppression of adaptive immunity to heterologous antigens during Plasmodium infection through hemozoin-induced failure of dendritic cell function. J. Biol. 5, 5 (2006).
103. Pashine, A., Valiante, N. M. & Ulmer, J. B. Targeting the innate immune response with improved vaccine adjuvants. Nature Med. 11, S63-S68 (2005).
104. Richards, R. L. et al. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun. 66, 2859-2865 (1998).
105. Skeiky, Y. A. et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20, 3292-3303 (2002). Advanced study using the TLR4 agonist MPL as an adjuvant for a recombinant vaccine against leishmaniasis.
106. + T cells.
107. Coban, C. et al. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect. Immun. 72, 584-588 (2004).
108. Cunha, M. G., Rodrigues, M. M. & Soares, I. S. Comparison of the immunogenic properties of recombinant proteins representing the Plasmodium vivax vaccine candidate MSP1(19) expressed in distinct bacterial vectors. Vaccine 20, 385-396 (2001).
109. Kumar, S. et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect. Immun. 72, 949-957 (2004).
110. Stacey, K. J. & Blackwell, J. M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67, 3719-3726 (1999).
111. + T cells in vivo. J. Immunol. 169, 3914-3919 (2002).
112. Fernandes, A. P. et al. Combined interleukin-12 and topical chemotherapy for established leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. J. Infect. Dis. 183, 1646-1652 (2001).
113. Michailowsky, V. et al. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemother. 42, 2549-2556 (1998).
114. Arevalo, I. et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847-1851 (2001). Study showing the effectiveness of adjunct therapy with the TLR8 agonist imiquimod in treating patients with cutaneous leishmaniasis.
115. Buates, S. & Matlashewski, G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179, 1485-1494 (1999).
116. Flynn, B., Wang, V., Sacks, D. L., Seder, R. A. & Verthelyi, D. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect. Immun. 73, 4948-4954 (2005). Study showing the prophylactic and therapeutic effectiveness of therapy with immunostimulatory oligodeoxynucleotides that contain CpG motifs in treating primates infected with L. major.
117. Schofield, L., Hewitt, M. C., Evans, K., Siomos, M. A. & Seeberger, P. H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418, 785-789 (2002). Vaccination with the synthetic carbohydrate moiety of P. falciparum GPI anchors protects mice from cytokine-mediate pathology observed during acute malaria.
118. Kim, L. et al. Toxoplasma gondii genotype determines MyD88-dependent signaling in infected macrophages. J. Immunol. 177, 2584-2591 (2006). Shows that the T. gondii strain type has a role in triggering MyD88 signalling pathways, and that virulent strains activate IL-12 production independently of this TLR adaptor molecule.
119. Dziarski, R. & Gupta, D. Peptidoglycan recognition in innate immunity. J. Endotoxin Res. 11, 304-310 (2005).
120. Kato, H. et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23, 19-28 (2005).
121. Balachandran, S., Thomas, E. & Barber, G. N. A FADD-dependent innate immune mechanism in mammalian cells. Nature 432, 401-405 (2004).